JAK1 and systemic lupus erythematosus: A selective JAK1 inhibitor (GSK2586184) had been proposed as a novel therapeutic agent in a phase IIb study that investigated patients with moderate-to-severe active SLE without renal or cerebral involvement who have failed standard therapy.